Monitoring new oral antithrombotics: what we should know before we can decide

被引：5
作者：
Al dieri, R. [1 ]
Hemker, H. C. [1 ]
机构：
[1] Cardiovasc Res Inst Maastricht, Synapse BV, NL-6200 MD Maastricht, Netherlands
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2010年 / 8卷 / 12期
关键词：
DIRECT THROMBIN INHIBITOR; HEALTHY MALE-SUBJECTS; POPULATION PHARMACOKINETICS; LABORATORY MONITORING; VENOUS THROMBOEMBOLISM; PHARMACODYNAMICS; GENERATION; HEPARIN; XIMELAGATRAN; HYPERCOAGULABILITY;
D O I：
10.1111/j.1538-7836.2010.04057.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2833 / 2835
页数：4
相关论文
共 50 条
  • [21] Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?
    Huttner, Angela
    Harbarth, Stephan
    Hope, William W.
    Lipman, Jeffrey
    Roberts, Jason A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (12) : 3178 - 3183
  • [22] Should we abandon the APTT for monitoring unfractionated heparin?
    Arachchillage, D. R. J.
    Kamani, F.
    Deplano, S.
    Banya, W.
    Laffan, M.
    THROMBOSIS RESEARCH, 2017, 157 : 157 - 161
  • [23] What we don't know about paracetamol in children
    Anderson, BJ
    PAEDIATRIC ANAESTHESIA, 1998, 8 (06): : 451 - 460
  • [24] Anticoagulation in cirrhosis patients: What don't we know?
    Northup, Patrick G.
    Intagliata, Nicolas M.
    LIVER INTERNATIONAL, 2011, 31 (01) : 4 - 6
  • [25] Incidence and Related Factors for Low-Extremity Deep Vein Thrombosis in Breast Cancer Patients Who Underwent Surgical Resection: What Do We Know and What Should We Care
    Chen, Liqiang
    Feng, Qiang
    Wang, Wenjuan
    Liu, Lanbo
    FRONTIERS IN SURGERY, 2022, 9
  • [26] Haemodialysis in patients treated with oral anticoagulant: should we heparinize?
    Krummel, Thierry
    Scheidt, Elise
    Borni-Duval, Claire
    Bazin, Dorothee
    Lefebvre, Francois
    Nguyen, Philippe
    Hannedouche, Thierry
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (04) : 906 - 913
  • [27] COVID-19 coagulopathy - what should we treat?
    Chowdary, Pratima
    EXPERIMENTAL PHYSIOLOGY, 2022, 107 (07) : 749 - 758
  • [28] Antibacterial medicinal chemistry - what can we design for?
    Parkes, Alastair L.
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (09) : 1005 - 1013
  • [29] What can we learn from kidney organoids?
    Dorison, Aude
    Forbes, Thomas A.
    Little, Melissa H.
    KIDNEY INTERNATIONAL, 2022, 102 (05) : 1013 - 1029
  • [30] Venous thromboembolism in palliative care patients: what do we know?
    Noble, Simon
    THROMBOSIS RESEARCH, 2020, 191 : S128 - S132
12345